Anavex Life Sciences Corp (AVXL) Given Consensus Recommendation of “Buy” by Brokerages

Anavex Life Sciences Corp (NASDAQ:AVXL) has earned an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $7.50.

Several equities analysts have weighed in on AVXL shares. HC Wainwright set a $10.00 target price on shares of Anavex Life Sciences and gave the company a “buy” rating in a report on Tuesday, July 10th. Maxim Group started coverage on shares of Anavex Life Sciences in a report on Monday, July 9th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, August 14th.

Large investors have recently bought and sold shares of the business. PHH Investments Ltd. boosted its holdings in Anavex Life Sciences by 169.6% in the 2nd quarter. PHH Investments Ltd. now owns 39,900 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 25,100 shares during the last quarter. Laurion Capital Management LP acquired a new position in Anavex Life Sciences in the 2nd quarter valued at about $134,000. Jane Street Group LLC acquired a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $157,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Anavex Life Sciences by 48.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 76,200 shares of the biotechnology company’s stock worth $211,000 after acquiring an additional 25,000 shares during the last quarter. Finally, LMR Partners LLP acquired a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $319,000. Institutional investors own 20.01% of the company’s stock.

NASDAQ AVXL traded down $0.05 during trading hours on Tuesday, hitting $2.44. 208,914 shares of the company’s stock traded hands, compared to its average volume of 432,170. Anavex Life Sciences has a 52-week low of $1.85 and a 52-week high of $5.15. The stock has a market cap of $124.03 million, a PE ratio of -7.39 and a beta of 1.32.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. On average, research analysts anticipate that Anavex Life Sciences will post -0.42 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply